These agonists synergistically suppressed GVHD disease by increasing the expression of immunosuppressive factors by the NFκB signaling pathway and inducing M2 macrophage-associated polarization and migratory cytokine secretion, an anti-inflammatory phenotype. Here, NFKB1 is linked to graft versus host disease.